{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:06:37Z","timestamp":1785186397111,"version":"3.55.0"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T00:00:00Z","timestamp":1554422400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Eisai, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12325-019-00947-0","type":"journal-article","created":{"date-parts":[[2019,4,5]],"date-time":"2019-04-05T16:49:45Z","timestamp":1554482985000},"page":"1266-1278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Metastatic Renal Cell Cancer: An Analysis of Reimbursement Decisions"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9654-0105","authenticated-orcid":false,"given":"Carina","family":"Schey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,5]]},"reference":[{"key":"947_CR1","unstructured":"Ljungberg B, Bensalah K, Bex A, et al. Guidelines on renal cell carcinoma. 2014. \n                    https:\/\/uroweb.org\/wp-content\/uploads\/10-Renal-Cell-Carcinoma_LR.pdf\n                    \n                  . Accessed Nov 2017."},{"issue":"1\u20136","key":"947_CR2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3233\/CBM-2011-0176","volume":"9","author":"P Cairns","year":"2011","unstructured":"Cairns P. Renal cell carcinoma. Cancer Biomark. 2011;9(1\u20136):461\u201373.","journal-title":"Cancer Biomark"},{"issue":"3","key":"947_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ctrv.2007.12.001","volume":"34","author":"K Gupta","year":"2008","unstructured":"Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008;34(3):193\u2013205. \n                    https:\/\/doi.org\/10.1016\/j.ctrv.2007.12.001\n                    \n                  .","journal-title":"Cancer Treat Rev"},{"key":"947_CR4","unstructured":"Cancer Research Institute. Immunotherapy for kidney cancer. 2017. \n                    https:\/\/www.cancerresearch.org\/we-are-cri\/home\/cancer-types\/kidney-cancer\n                    \n                  . Accessed Nov 2017."},{"issue":"11","key":"947_CR5","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.4161\/21645515.2014.983857","volume":"10","author":"A Kirner","year":"2014","unstructured":"Kirner A, Mayer-Mokler A, Reinhardt C. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer. Human Vacc Immunother. 2014;10(11):3179\u201389. \n                    https:\/\/doi.org\/10.4161\/21645515.2014.983857\n                    \n                  .","journal-title":"Human Vacc Immunother"},{"key":"947_CR6","unstructured":"National Cancer Institute. SEER stat fact sheets: kidney and renal pelvis cancer. 2015. \n                    https:\/\/seer.cancer.gov\/statfacts\/html\/kidrp.html\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR7","unstructured":"Campbell MT, Jonasch E. Updates in the systemic treatment of patients with metastatic renal cell carcinoma. \n                    https:\/\/gucasym.org\/daily-news\/updates-systemic-treatmentpatients-metastatic-renal-cell-carcinoma\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR8","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology\u2014kidney cancer. 2017. \n                    https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3308682\/\n                    \n                  . Accessed Nov 2017."},{"issue":"suppl 5","key":"947_CR9","doi-asserted-by":"publisher","first-page":"v58","DOI":"10.1093\/annonc\/mdw328","volume":"27","author":"B Escudier","year":"2016","unstructured":"Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v58\u201368. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdw328\n                    \n                  .","journal-title":"Ann Oncol"},{"key":"947_CR10","unstructured":"Canadian Agency for Drugs and Technology (CADTH). \n                    https:\/\/www.cadth.ca\/\n                    \n                  ."},{"key":"947_CR11","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (HAS). \n                    https:\/\/www.has-sante.fr\/portail\/\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR12","unstructured":"Gemeinsamer Bundesausschuss (G-BA). \n                    https:\/\/www.g-ba.de\/\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR13","unstructured":"Institute for Quality and Efficiency in Health Care (IQWiG). \n                    https:\/\/www.iqwig.de\/en\/home.2724.html\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR14","unstructured":"Tandv\u00e5rds- och l\u00e4kemedelsf\u00f6rm\u00e5nsverket (TLV). \n                    https:\/\/www.tlv.se\/in-english\/in-english\/\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR15","unstructured":"Scottish Medicines Consortium (SMC). \n                    https:\/\/www.scottishmedicines.org.uk\/\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR16","unstructured":"NICE TA178. Bevacizumab (first-line), sorafenib (firstand second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and\/or metastatic renal cell carcinoma. 2009. \n                    https:\/\/www.nice.org.uk\/guidance\/ta178\/resources\/bevacizumab-firstline-sorafenib-first-and-secondline-sunitinib-secondline-and-temsirolimus-firstline-for-the-treatment-of-advanced-andor-metastatic-renal-cell-carcinoma-pdf-82598442394309\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR17","unstructured":"Therapeutic Goods Administration. AusPAR Attachment 1: Product Information for Bevacizumab. 2017. \n                    https:\/\/search.tga.gov.au\/s\/search.html?collection=tga-websites-web&query=bevacizumab+renal+cell\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR18","unstructured":"Roche Ltd. Availability of new, innovative and specialist cancer drugs in Australia - Submission to the Senate Community Affairs References Committee 2015. \n                    http:\/\/www.roche-australia.com\/content\/dam\/roche_australia\/en_AU\/policy\/2015-02%20Senate%20Inquiry.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR19","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Transparency Commission: Proleukin. 2014. \n                    http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2015-10\/proleukin_version_anglaise_ct13702.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR20","unstructured":"PBAC. Public Summary Document: Sunitinib. 2008. \n                    http:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2008-07\/Sunitinib__Final_PSD_7-9_Pfizer.pdf;jsessionid=kon95ccgxtmk11uqjsi8cvyly\/\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR21","unstructured":"NICE TA169. Sunitinib for the first-line treatment of advanced and\/or metastatic renal cell carcinoma. 2009. \n                    https:\/\/www.nice.org.uk\/guidance\/ta169\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR22","unstructured":"G-BA. Beschluss des Gemeinsamen Bundesausschusses \u00fcber die Einleitung eines Stellungnahmeverfahrens zur \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage XI - Besondere Arzneimittel Besondere Arzneimittel nach \u00a7 73d SGB V bei der Behandlung des metastasierten und\/oder fortgeschrittenen Nierenzellkarzinoms: Bevacizumab, Sorafenib, Sunitinib, Temsirolimus. 2009. \n                    https:\/\/www.g-ba.de\/downloads\/39-261-879\/2009-09-17-AMR13-SN-Nierenzellkarzinom.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR23","unstructured":"L\u00e4kemedelsf\u00f6rm\u00e5nsn\u00e4mnden L\u00c4KEMEDELSF\u00d6RM\u00c5NSN\u00c4MNDENS BESLUT 2006. L\u00c4KEMEDELSF\u00d6RM\u00c5NSN\u00c4MNDENS BESLUT. Accessed June 2017."},{"key":"947_CR24","unstructured":"SMC. sunitinib 12.5mg, 25mg, 50mg capsules (Sutent). 2007. \n                    https:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/384_07_sunitinib_capsules__Sutent_\/sunitinib_12.5mg__25mg__50mg_capsules__Sutent_\n                    \n                  ."},{"key":"947_CR25","unstructured":"CADTH. CEDAC Final recommendation on reconsideration and reasons for recommendation-sunitinib maleate-sutent re-submission. 2007. \n                    https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/complete\/cdr_complete_Sutent_e_April-26-2007%20.pdf\n                    \n                  . Accessed Nov 2017."},{"issue":"1","key":"947_CR26","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1111\/j.1524-4733.2009.00616.x","volume":"13","author":"M Hoyle","year":"2010","unstructured":"Hoyle M, Green C, Thompson-Coon J, et al. Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma. Value Health. 2010;13(1):55\u201360. \n                    https:\/\/doi.org\/10.1111\/j.1524-4733.2009.00616.x\n                    \n                  .","journal-title":"Value Health"},{"issue":"2","key":"947_CR27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125\u201334. \n                    https:\/\/doi.org\/10.1056\/NEJMoa060655\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"947_CR28","unstructured":"PBS. Sorafenib, tablet, 200\u00a0mg (as tosylate), Nexavar\u00ae. 2012. \n                    http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2012-11\/sorafenib\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR29","unstructured":"CADTH. CEDAC Final Recommendation on Reconsideration and Reasons for Recommendation - Sorafenib (Nexavar). 2007. \n                    https:\/\/www.cadth.ca\/sites\/default\/files\/cdr\/complete\/cdr_complete_Nexavar_Fe-28-07.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR30","unstructured":"SMC. Sorafenib 200mg tablets (Nexavar) No.321\/06). 2006. \n                    https:\/\/www.scottishmedicines.org.uk\/files\/sorafenib_200mg_tablets_Nexavar_321_06.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR31","unstructured":"PBS. Temsirolimus, injection set containing 1 vial of powder for IV infusion 25\u00a0mg and 1 vial diluent, Torisel\u00ae. 2008. \n                    http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2008-07\/pbac-psd-temsirolimus-july08\n                    \n                  . Accessed Nov 2017."},{"issue":"22","key":"947_CR32","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271\u201381.","journal-title":"N Engl J Med"},{"key":"947_CR33","unstructured":"HAS. Transparency Committee: TORISEL (CIP: 571 783-7). 2008. \n                    https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2010-12\/torisel_ct_5270.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/CE.S98687","volume":"11","author":"S Buti","year":"2016","unstructured":"Buti S, Leonetti A, Dallatomasina A, Bersanelli M. Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy. Core Evid. 2016;11:23\u201336. \n                    https:\/\/doi.org\/10.2147\/CE.S98687\n                    \n                  .","journal-title":"Core Evid"},{"key":"947_CR35","unstructured":"PBS. EVEROLIMUS, tablets, 5\u00a0mg and 10\u00a0mg, Afinitor\u00ae, Novartis Pharmaceuticals Australia Pty Ltd. 2014. \n                    http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2014-03\/everolimus-rcc\n                    \n                  ."},{"key":"947_CR36","unstructured":"HAS. Transparency Committee: AFINITOR (everolimus). 2010. \n                    http:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2010-12\/afinitor_ct_7009.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR37","unstructured":"G-BA. Beschluss des Gemeinsamen Bundesausschusses \u00fcber die Einleitung eines Stellungnahmeverfahrens zur \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage XI\u2014Besondere Arzneimittel Besondere Arzneimittel nach \u00a7 73d SGB V bei der Behandlung des metastasierten und\/oder fortgeschrittenen Nierenzellkarzinoms: Everolimus. 2009. \n                    https:\/\/www.g-ba.de\/downloads\/39-261-1054\/2009-12-17-AMR11-SN-Everolimus.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR38","unstructured":"SMC. Re-Submission: everolimus 2.5\u00a0mg, 5\u00a0mg and 10\u00a0mg tablets (Afinitor\u00ae) SMC No. (595\/10) 2014. \n                    https:\/\/www.scottishmedicines.org.uk\/files\/advice\/everolimus_Afintor_Resubmission_FINAL_Oct_2014_Updated_30.10.14_for_website.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR39","unstructured":"TLV. SAKEN Ans\u00f6kan inom l\u00e4kemedelsf\u00f6rm\u00e5nerna. BESLUT. Afinitor. 2010. \n                    https:\/\/www.tlv.se\/upload\/beslut_2010\/bes100907-afinitor.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR40","unstructured":"NICE TA432. Everolimus for advanced renal cell carcinoma after previous treatment. 2017. \n                    https:\/\/www.nice.org.uk\/guidance\/ta432\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR41","unstructured":"CADTH. Drugs reviewed under the Joint Oncology Drug Review Process from 2007 to 2011. 2014. \n                    https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr-ijodr-drugs-provfund.pdf\n                    \n                  . Accessed Nov 2017."},{"issue":"18","key":"947_CR42","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer. 2010;116(18):4256\u201365. \n                    https:\/\/doi.org\/10.1002\/cncr.25219\n                    \n                  .","journal-title":"Cancer"},{"issue":"8","key":"947_CR43","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1303989\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"947_CR44","unstructured":"Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee (pERC)-Final Recommendation-Pazopanib in metastatic renal cell carcinoma. 2013. \n                    https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr-votrientmrccre-fn-rec.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR45","unstructured":"NICE TA215. Pazopanib for the first-line treatment of advanced renal cell carcinoma. 2013. \n                    https:\/\/www.nice.org.uk\/guidance\/ta215\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR46","unstructured":"HAS. Commission de la Transparence - Votrient. 2015. \n                    http:\/\/www.has-sante.fr\/portail\/upload\/docs\/evamed\/CT-13937_VOTRIENT_PIC_REEV_AvisPostAud_CT13937.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR47","unstructured":"TLV. Beslut-Votrient. 2013. \n                    http:\/\/www.tlv.se\/Upload\/Beslut_2013\/bes131212-votrient.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR48","unstructured":"SMC. Pazopanib 200\u00a0mg, 400\u00a0mg film-coated tablets (Votrient\u00ae) SMC No.(676\/11). 2011. \n                    https:\/\/www.scottishmedicines.org.uk\/files\/advice\/pazopanib_Votrient_FINAL_February_2011.doc_for_website.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR49","unstructured":"PBS. Pazopanib, tablet, 200\u00a0mg and 400\u00a0mg (as hydrochloride), Votrient\u00ae\u2014March 2012. 2012. \n                    http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2012-03\/pazopanib\n                    \n                  . Accessed 30 June 2017."},{"key":"947_CR50","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4137\/CMO.S10594","volume":"7","author":"M Gross-Goupil","year":"2013","unstructured":"Gross-Goupil M, Francois L, Quivy A, Ravaud A. Axitinib: a review of its safety and efficacy in the treatment of adults with advanced renal cell carcinoma. Clin Med Insights Oncol. 2013;7:269\u201377. \n                    https:\/\/doi.org\/10.4137\/CMO.S10594\n                    \n                  .","journal-title":"Clin Med Insights Oncol"},{"issue":"9807","key":"947_CR51","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011;378(9807):1931\u20139. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(11)61613-9\n                    \n                  .","journal-title":"Lancet"},{"issue":"8","key":"947_CR52","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1200\/JCO.2013.50.3961","volume":"32","author":"TE Hutson","year":"2014","unstructured":"Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(8):760\u20137. \n                    https:\/\/doi.org\/10.1200\/jco.2013.50.3961\n                    \n                  .","journal-title":"J Clin Oncol"},{"key":"947_CR53","unstructured":"Pan-Canadian Oncology Drug Review. pCODR Expert Review Committee (pERC) Final recommendation-axitinib. 2013. \n                    https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr-inlytamrcc-fn-rec.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR54","unstructured":"NICE TA333. Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment. 2015. \n                    https:\/\/www.nice.org.uk\/guidance\/ta333\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR55","unstructured":"HAS. Commission de la Transparence - INLYTA. 2013. \n                    http:\/\/www.has-sante.fr\/portail\/upload\/docs\/evamed\/CT-12556_INLYTA%20Ins%20Avis%202_CT%2012556.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR56","unstructured":"IQWiG. Axitinib \u2013 Benefit assessment according to \u00a7 35a Social Code Book V1. 2012. \n                    https:\/\/www.iqwig.de\/download\/A12-14_Axitinib_Extract_of_dossier_assessment.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR57","unstructured":"TLV. Inlyta ing\u00e5r i h\u00f6gkostnadsskyddet. 2013. \n                    https:\/\/www.tlv.se\/beslut\/beslut-lakemedel\/generell-subvention\/inlyta-ingar-i-hogkostnadsskyddet\/\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR58","unstructured":"SMC. Axitinib (Inlyta). 2013. \n                    https:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/855_13_axitinib_Inlyta\/axitinib_Inlyta_Resubmission\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR59","unstructured":"PBS. Axitinib, tablet, 1\u00a0mg and 5\u00a0mg, Inlyta\u00ae - Nov 2013. 2013. \n                    http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2013-11\/axitinib\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR60","unstructured":"PBAC. AXITINIB tablets, 1\u00a0mg & 5\u00a0mg; Inlyta\u00ae; Pfizer Australia Pty Ltd. 2014. \n                    http:\/\/www.pbs.gov.au\/industry\/listing\/elements\/pbac-meetings\/psd\/2014-11\/files\/axitinib-psd-11-2014.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR61","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.eururo.2017.07.041","volume":"15","author":"M Sarfaty","year":"2017","unstructured":"Sarfaty M, Leshno M, Gordon N, et al. Cost effectiveness of nivolumab in advanced renal cell carcinoma. Eur Urol. 2017;15:8. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2017.07.041\n                    \n                  .","journal-title":"Eur Urol"},{"key":"947_CR62","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2147\/DDDT.S110209","volume":"11","author":"VA Venur","year":"2017","unstructured":"Venur VA, Joshi M, Nepple KG, Zakharia Y. Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Des Dev Ther. 2017;11:1175\u201382. \n                    https:\/\/doi.org\/10.2147\/DDDT.S110209\n                    \n                  .","journal-title":"Drug Des Dev Ther"},{"issue":"19","key":"947_CR63","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1803\u201313. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1510665\n                    \n                  .","journal-title":"N Engl J Med"},{"key":"947_CR64","unstructured":"pCODR. pan-Canadian Oncology Drug Review. Final economic guidance report. Nivolumab (Opdivo) for metastatic renal cell carcinoma. 2016. \n                    https:\/\/www.cadth.ca\/sites\/default\/files\/pcodr\/pcodr_nivolumab_opdivo_mrcc_fn_egr.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR65","unstructured":"NICE TA417. Nivolumab for previously treated advanced renal cell carcinoma. 2016. \n                    https:\/\/www.nice.org.uk\/guidance\/ta417\/chapter\/4-Committee-discussion#clinical-effectiveness\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR66","unstructured":"HAS. Commission de la Transparence. Avis: nivolumab. 2016. \n                    http:\/\/www.has-sante.fr\/portail\/upload\/docs\/evamed\/CT-15277_OPDIVO_cancer_rein_PIC_INS_Avis2_CT15277.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR67","unstructured":"IQWiG. IQWiG Reports\u2014Commission No. A16-24. Nivolumab (renal cell carcinoma)-benefit assessment according to \u00a735a Social Code Book V1. 2016. \n                    https:\/\/www.iqwig.de\/download\/A16-24_Nivolumab_Extract-of-dossier-assessment.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR68","unstructured":"PBAC. Nov 2016 PBAC outcomes\u2014subsequent decisions not to recommend. 2016. \n                    https:\/\/engonetuf.blob.core.windows.net\/assets\/uploads\/files\/subsequent-decisions-not-to-recommend-2016-11.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR69","unstructured":"PBAC. NIVOLUMAB, Opdivo\u00ae, Bristol-Myers Squibb Australia Pty Ltd. (PDF on file). 2017."},{"key":"947_CR70","unstructured":"SMC. Nivolumab (Opdivo). 2017. \n                    https:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/1188_16_nivolumab_Opdivo_for_renal_cell_carcinoma\/nivolumab_Opdivo_Resubmission\n                    \n                  . Accessed Nov 2017."},{"issue":"12","key":"947_CR71","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298\u2013308. \n                    https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0264\n                    \n                  .","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"947_CR72","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","volume":"17","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917\u201327. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30107-3\n                    \n                  .","journal-title":"Lancet Oncol"},{"key":"947_CR73","unstructured":"HAS. Commission de la Transparence: Cabozantinib. 2017. \n                    http:\/\/www.has-sante.fr\/portail\/upload\/docs\/evamed\/CT-15738_CABOMETYX_PIC_INS_AvisPostObs_CT15738.pdf\n                    \n                  . Accessed Nov 2017."},{"key":"947_CR74","unstructured":"IQWiG. [A16-69] Cabozantinib (renal cell carcinoma)\u2014benefit assessment according to \u00a735a Social Code Book V. 2016. \n                    https:\/\/www.iqwig.de\/en\/projects-results\/projects\/drug-assessment\/a16-69-cabozantinib-renal-cell-carcinoma-benefit-assessment-according-to-35a-social-code-book-v.7687.html\n                    \n                  . Accessed Nov 2017."},{"issue":"5","key":"947_CR75","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/oxfordjournals.annonc.a010644","volume":"7","author":"JM Tourani","year":"1996","unstructured":"Tourani JM, Lucas V, Mayeur D, et al. Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial. Ann Oncol. 1996;7(5):525\u20138.","journal-title":"Ann Oncol"},{"key":"947_CR76","unstructured":"Fund CD. \n                    https:\/\/www.england.nhs.uk\/cancer\/cdf\/\n                    \n                  . Accessed Nov 2017."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00947-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-00947-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-00947-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T23:07:23Z","timestamp":1585955243000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-00947-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,5]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["947"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-00947-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,5]]},"assertion":[{"value":"26 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}